P/B
2,4
Recursion Pharmaceuticals
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery.
$2.2B
Market Cap • 11/6/2026
2016
(10 years)
Founded
2021
(5 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
32,2
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
1,5
EPS
—
Market Cap
Market Cap
2,2B
EV
1,7B
EV/Revenue
25,2
EV/EBITDA
-4,1
EV/EBIT
-3,5
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-10%
Total Yield
-10%
Payout
0%
Retained Earnings
-2,4B
Profitability
Gross Margin
29,2%
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
546%
Capex/Revenue
2,9%
Capex/D&A
2,6%
Capex/OCF
-0,6%
SBC/OCF
—
% PPE
12,5%
% Goodwill
13,2%
ROE
—
ROIC
—
Growth
CAGR Revenue 5Y
45,9%
CAGR Op. Income 5Y
28,1%
CAGR Net Income 5Y
26,4%
CAGR EPS 5Y
-21,9%
CAGR OCF 5Y
28,4%
Leverage
N.D./EBITDA
1,1
Debt/Equity
0%
Current Ratio
5
Quick Ratio
4,8
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!